<strike id="1rpfh"><dl id="1rpfh"><del id="1rpfh"></del></dl></strike>
<span id="1rpfh"><dl id="1rpfh"><strike id="1rpfh"></strike></dl></span>
<strike id="1rpfh"></strike>
<strike id="1rpfh"><dl id="1rpfh"></dl></strike>
<ruby id="1rpfh"><dl id="1rpfh"><del id="1rpfh"></del></dl></ruby>

Pharmacovigilance


A.1.5 – Pharmacovigilance notice

This website has not been designed to collect safety information related to Bristol-Myers Squibb products.

Healthcare Professionals?

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website:??www.hpra.ie; E-mail:??medsafety@hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or??medical.information@bms.com

Patients?

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website:?www.hpra.ie; E-mail:?medsafety@hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.

Side effects should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or?medical.information@bms.com

Healthcare professionals and patients should also report Product Quality Complaints to Bristol-Myers Squibb Medical Information on 1 800 749 749 or?medical.information@bms.com

Approval number: NOIE2003264
Date: May 2020

成片免费日本wang